Kidney transplant breakthrough: Biopsy-Guided drug adjustments could save more grafts
NCT ID NCT02444429
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 26 times
Summary
This study tested whether a routine biopsy three months after kidney transplant can help doctors personalize immunosuppressive therapy. 346 patients were split into two groups: those with mild inflammation received extra steroids, while those with no inflammation had their steroids reduced. The goal was to improve graft survival and reduce side effects from lifelong medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Département de Néphrologie et Transplantation d'Organes - Hôpital Rangueil - CHU de Toulouse
Toulouse, 31059, France
-
Institut de Transplantation, Urologie et Néphrologie (ITUN) - CHU de Nantes
Nantes, 44093, France
-
Service de Néphrologie - Hôpital Claude Huriez - CHU de Lille
Lille, 59037, France
-
Service de Néphrologie et Transplantation - Nouvel Hôpital Civil - CHRU Strasbourg
Strasbourg, 67091, France
-
Service de Néphrologie, Hémodialyse, Transplantations Rénales - Hôpital de la Cavale Blanche - CHU de Brest
Brest, 29609, France
-
Service de Néphrologie, Transplantation et Immunologie Clinique - Hôpital Edouard Herriot - Hospices Civils de Lyon
Lyon, 69437, France
-
Service de Néphrologie,Transplantation, Dialyse I - Hôpital Pellegrin - CHU Bordeaux
Bordeaux, 33000, France
-
Service de Transplantation - Hôpital Universitaire Necker
Paris, 75015, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Corticosteroid boluses (methylprednisolone) and corticosteroid withdrawal
What this could lead to
If successful, this approach could help tailor immunosuppression after kidney transplant, potentially reducing graft loss and side effects from lifelong medication.
What could go wrong
This is a completed phase 3 trial, but results may not apply to all transplant patients. The strategy involves risks from biopsies and changes in medication.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.